Overview
Breyanzi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several types of relapsed or refractory lymphoma, including large B-cell lymphoma (LBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma grade 3B, mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL) in adults who have previously received specific treatments. Eligibility depends on the type of lymphoma and the number and types of prior therapies a person has received. For example, Breyanzi may be used for people whose disease is refractory (not responding) to, or has relapsed after, prior treatments, including chemoimmunotherapy or specific targeted therapies. Breyanzi is not indicated for people with primary central nervous system lymphoma. Breyanzi is also known by its drug name, lisocabtagene maraleucel.

Breyanzi is a type of immunotherapy called chimeric antigen receptor (CAR) T-cell therapy. Breyanzi is made from a person’s own T cells that have been harvested and genetically engineered to target lymphoma cells. Breyanzi is believed to work by attacking and killing lymphoma cells.

How do I take it?
Prescribing information states that Breyanzi is administered as a one-time intravenous infusion after completing lymphodepleting chemotherapy. The treatment involves collecting the recipient’s T cells, genetically modifying them to target lymphoma cells, and then infusing them back into the person. Premedication with acetaminophen and an H1 antihistamine is recommended before the infusion. Breyanzi should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Breyanzi include fever, cytokine release syndrome (CRS; an intense immune reaction), fatigue, muscle and joint pain, nausea, encephalopathy (brain dysfunction), edema (swelling), and diarrhea. Laboratory abnormalities may include low lymphocyte count, low neutrophil count (a type of white blood cell), low platelet count, and low hemoglobin (the oxygen-carrying component of blood).

Rare but serious side effects may include severe or life-threatening cytokine release syndrome, neurologic toxicities such as confusion or seizures, severe infections, prolonged cytopenias (low blood counts lasting several weeks), hypogammaglobulinemia (low antibody levels), severe hypersensitivity reactions (allergic reactions), and the development of secondary hematological malignancies (new cancers of blood cells, including T cell malignancies).

For more details about this treatment, visit:
Label: Breyanzi — Lisocabtagene Maraleucel Kit — DailyMed

Breyanzi (Lisocabtagene Maraleucel) Suspension for Intravenous Infusion — Bristol-Myers Squibb